PMID- 34660809
OWN - NLM
STAT- MEDLINE
DCOM- 20220208
LR  - 20220427
IS  - 2314-6753 (Electronic)
IS  - 2314-6745 (Print)
VI  - 2021
DP  - 2021
TI  - Liraglutide Decreases Liver Fat Content and Serum Fibroblast Growth Factor 21 
      Levels in Newly Diagnosed Overweight Patients with Type 2 Diabetes and 
      Nonalcoholic Fatty Liver Disease.
PG  - 3715026
LID - 10.1155/2021/3715026 [doi]
LID - 3715026
AB  - PURPOSES: In this study, we aimed to verify plasma fibroblast growth factor 21 
      (FGF21) elevation in newly diagnosed overweight patients with type 2 diabetes 
      mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD) and to evaluate the 
      effectiveness of liraglutide on reducing liver fat content and serum (FGF21) 
      levels in those patients. METHODS: A 12-week, single-center, prospective study 
      was conducted. Twenty newly diagnosed overweight patients with T2DM and NAFLD 
      were recruited. Twenty healthy age, sex, and body mass index (BMI) matched 
      subjects were enrolled as the control group. Enzyme-linked immunosorbent assay 
      was used to measure serum FGF21 levels. Liver fat content was determined using 
      the 3.0 T whole-body MRI scanner. RESULTS: Those newly diagnosed overweight 
      patients with T2DM and NAFLD had a BMI of 27.6 +/- 0.5 kg/m(2). They had higher 
      levels of FGF21 (159.6 +/- 35.7 vs. 124.1 +/- 42.9 pg/ml, P < 0.001) and increased 
      liver fat content (19.3 +/- 9.4 vs. 4.5 +/- 0.6%, P < 0.001) compared to the 
      controls. Liraglutide treatment for 12 weeks induced a significant 4.9 kg weight 
      loss (95% confidence interval (CI): -6.1, -3.7, P < 0.001), which was equivalent 
      to a relative reduction of 6.8% (95% CI: 5.3%, 8.3%, P < 0.001). FGF21 levels 
      decreased after the 12-week liraglutide treatment (159.6 +/- 35.7 vs. 124.2 +/- 
      27.8 pg/ml, P = 0.006). There was a positive correlation between relative changes 
      of liver fat content and relative change of FGF21 (r = 0.645, P = 0.002). FGF21 
      levels significantly decreased in patients who had a significant decrease in 
      liver fat content (>/=29%) (95% CI: -262.8, -55.1, P = 0.006); however, there was 
      no significant change in the patients without a significant decrease in liver fat 
      content (<29%) (95% CI: -60.0, 54.1, P = 0.899). CONCLUSIONS: Liraglutide 
      treatment reduced both liver fat content and FGF21 levels in newly diagnosed 
      overweight patients with T2DM and NAFLD. FGF21 may be a potential biomarker for 
      evaluating the effects of liraglutide treatment on hepatic fat and glucose 
      metabolism.
CI  - Copyright (c) 2021 Xinyue Li et al.
FAU - Li, Xinyue
AU  - Li X
AD  - Department of Radiology, Beijing Chao Yang Hospital, Capital Medical University, 
      No. 8, Gong ti South Road, Chao Yang District, Beijing 100020, China.
FAU - Wu, Xiaojuan
AU  - Wu X
AUID- ORCID: 0000-0002-7320-2354
AD  - Department of Endocrinology, Beijing Chao Yang Hospital, Capital Medical 
      University, No. 8, Gong ti South Road, Chao Yang District, Beijing 100020, China.
FAU - Jia, Yumei
AU  - Jia Y
AD  - Department of Endocrinology, Beijing Chao Yang Hospital, Capital Medical 
      University, No. 8, Gong ti South Road, Chao Yang District, Beijing 100020, China.
FAU - Fu, Jing
AU  - Fu J
AD  - Department of Endocrinology, Beijing Chao Yang Hospital, Capital Medical 
      University, No. 8, Gong ti South Road, Chao Yang District, Beijing 100020, China.
FAU - Zhang, Lin
AU  - Zhang L
AD  - Department of Endocrinology, Beijing Chao Yang Hospital, Capital Medical 
      University, No. 8, Gong ti South Road, Chao Yang District, Beijing 100020, China.
FAU - Jiang, Tao
AU  - Jiang T
AUID- ORCID: 0000-0001-9229-4330
AD  - Department of Radiology, Beijing Chao Yang Hospital, Capital Medical University, 
      No. 8, Gong ti South Road, Chao Yang District, Beijing 100020, China.
FAU - Liu, Jia
AU  - Liu J
AUID- ORCID: 0000-0002-6957-3814
AD  - Department of Endocrinology, Beijing Chao Yang Hospital, Capital Medical 
      University, No. 8, Gong ti South Road, Chao Yang District, Beijing 100020, China.
FAU - Wang, Guang
AU  - Wang G
AUID- ORCID: 0000-0001-9321-5200
AD  - Department of Endocrinology, Beijing Chao Yang Hospital, Capital Medical 
      University, No. 8, Gong ti South Road, Chao Yang District, Beijing 100020, China.
LA  - eng
PT  - Journal Article
DEP - 20211008
PL  - England
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (FGF21 protein, human)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Incretins)
RN  - 62031-54-3 (Fibroblast Growth Factors)
RN  - 839I73S42A (Liraglutide)
SB  - IM
MH  - Adiposity/*drug effects
MH  - Adult
MH  - Beijing
MH  - Biomarkers/blood
MH  - Blood Glucose/drug effects/metabolism
MH  - Case-Control Studies
MH  - Diabetes Mellitus, Type 2/blood/diagnosis/*drug therapy
MH  - Down-Regulation
MH  - Female
MH  - Fibroblast Growth Factors/*blood
MH  - Humans
MH  - Hypoglycemic Agents/adverse effects/*therapeutic use
MH  - Incretins/adverse effects/*therapeutic use
MH  - Liraglutide/adverse effects/*therapeutic use
MH  - Liver/diagnostic imaging/*drug effects/metabolism
MH  - Male
MH  - Middle Aged
MH  - Non-alcoholic Fatty Liver Disease/blood/diagnostic imaging/*drug therapy
MH  - Overweight/blood/diagnosis/*drug therapy
MH  - Prospective Studies
MH  - Time Factors
MH  - Treatment Outcome
PMC - PMC8519721
COIS- No competing financial interests exist.
EDAT- 2021/10/19 06:00
MHDA- 2022/02/09 06:00
PMCR- 2021/10/08
CRDT- 2021/10/18 09:09
PHST- 2021/06/07 00:00 [received]
PHST- 2021/09/14 00:00 [revised]
PHST- 2021/09/20 00:00 [accepted]
PHST- 2021/10/18 09:09 [entrez]
PHST- 2021/10/19 06:00 [pubmed]
PHST- 2022/02/09 06:00 [medline]
PHST- 2021/10/08 00:00 [pmc-release]
AID - 10.1155/2021/3715026 [doi]
PST - epublish
SO  - J Diabetes Res. 2021 Oct 8;2021:3715026. doi: 10.1155/2021/3715026. eCollection 
      2021.